3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Advanced Malignancies
2
Urothelial Cancer
1
Thyroid Neoplasms
1
Solid Tumors, KRAS Mutation
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Opioid-Related Disorders
1
Lung Neoplasms
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Leiomyosarcoma
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
Hematologic Neoplasms
1
Healthy Adult Participants
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Cancer Pain
1
Interventions
atezolizumab
3
Specimen Handling
2
spartalizumab
1
selinexor
1
sargramostim
1
pembrolizumab
1
pazopanib
1
fludarabine
1
cediranib
1
cabozantinib
1
atropine sulfate-diphenoxylate hydrochloride drug combination
1
anlotinib
1
Zoledronic Acid
1
Warfarin
1
Vitamin B 6
1
Thyroxine
1
Tablets
1
Sunitinib
1
Rosuvastatin Calcium
1
Radiotherapy
1
Radiation
1
Pyridoxine
1
Promethazine
1
Prochlorperazine
1
Petrolatum
1
Midazolam
1
Lorazepam
1
Loperamide
1
Immunoglobulin G
1
Ifosfamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Alveolar Soft Part
×
Midazolam
×
1 year
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled